Economic Benefits of Sport Fishing and Angler Wildlife Watching in Pennsylvania: A Comment

2002 ◽  
Vol 41 (2) ◽  
pp. 210-211 ◽  
Author(s):  
Roger H. Coupal ◽  
Chris T. Bastian ◽  
David T. Taylor
2001 ◽  
Vol 40 (1) ◽  
pp. 68-78 ◽  
Author(s):  
Arun Upneja ◽  
Elwood L. Shafer ◽  
Wonseok Seo ◽  
Jihwan Yoon

Author(s):  
V. A. Hernández-Trejo ◽  
G. Ponce-Díaz Germán ◽  
D. Lluch-Belda ◽  
L. F. Beltrán-Morales

2014 ◽  
Vol 44 (4) ◽  
pp. 527-532 ◽  
Author(s):  
Mario J. F. Thomé-Souza ◽  
Michael J. Maceina ◽  
Bruce R. Forsberg ◽  
Bruce G. Marshall ◽  
Álvaro L. Carvalho

Sport fishing for peacock bass Cichla spp. in the Brazilian Amazon has increased in popularity and attracts anglers who generate significant economic benefits in rural regions. The sustainability of this fishery is partly dependent on the survival of fish caught through catch-and-release fishing. The objective of this work was to investigate, hooking mortality of Cichla spp., including speckled peacock bass (C. temensis Humbolt), butterfly peacock bass (C. orinocensis Humbolt), and popoca peacock bass (C. monoculus Agassiz) in the basin of the Negro River, the largest tributary of the Amazon River. Fish were caught at two different sites using artificial lures, transported to pens anchored in the river and monitored for 72 hours. A total of 162 individual peacock bass were captured and hooking mortality (mean % ± 95% confidence intervals) was calculated. Mean mortality was 3.5% (± 5.0), 2.3% (± 3.5) and 5.2% (± 10.2) for speckled peacock bass, butterfly peacock bass, and popoca peacock bass, respectively. Lengths of captured fish ranged from 26 to 79 cm (standard length), however, only fish under 42 cm died. This research suggests that catch-and-release sport fishing of peacock bass does not result in substantial mortality in the Negro River basin.


1980 ◽  
Vol 19 (03) ◽  
pp. 125-132
Author(s):  
G. S. Lodwick ◽  
C. R. Wickizer ◽  
E. Dickhaus

The Missouri Automated Radiology System recently passed its tenth year of clinical operation at the University of Missouri. This article presents the views of a radiologist who has been instrumental in the conceptual development and administrative support of MARS for most of this period, an economist who evaluated MARS from 1972 to 1974 as part of her doctoral dissertation, and a computer scientist who has worked for two years in the development of a Standard MUMPS version of MARS. The first section provides a historical perspective. The second deals with economic considerations of the present MARS system, and suggests those improvements which offer the greatest economic benefits. The final section discusses the new approaches employed in the latest version of MARS, as well as areas for further application in the overall radiology and hospital environment. A complete bibliography on MARS is provided for further reading.


1997 ◽  
Vol 77 (03) ◽  
pp. 436-439 ◽  
Author(s):  
Armando Tripodi ◽  
Barbara Negri ◽  
Rogier M Bertina ◽  
Pier Mannuccio Mannucci

SummaryThe factor V (FV) mutation Q506 that causes resistance to activated protein C (APC) is the genetic defect associated most frequently with venous thrombosis. The laboratory diagnosis can be made by DNA analysis or by clotting tests that measure the degree of prolongation of plasma clotting time upon addition of APC. Home-made and commercial methods are available but no comparative evaluation of their diagnostic efficacy has so far been reported. Eighty frozen coded plasma samples from carriers and non-carriers of the FV: Q506 mutation, diagnosed by DNA analysis, were sent to 8 experienced laboratories that were asked to analyze these samples in blind with their own APC resistance tests. The APTT methods were highly variable in their capacity to discriminate between carriers and non-carriers but this capacity increased dramatically when samples were diluted with FV-deficient plasma before analysis, bringing the sensitivity and specificity of these tests to 100%. The best discrimination was obtained with methods in which fibrin formation is triggered by the addition of activated factor X or Russell viper venom. In conclusion, this study provides evidence that some coagulation tests are able to distinguish carriers of the FV: Q506 mutation from non-carriers as well as the DNA test. They are inexpensive and easy to perform. Their use in large-scale clinical trials should be of help to determine the medical and economic benefits of screening healthy individuals for the mutation before they are exposed to such risk factors for venous thrombosis as surgery, pregnancy and oral contraceptives.


Sign in / Sign up

Export Citation Format

Share Document